Skip to main content
. 2019 May 18;37(9):1129–1138. doi: 10.1007/s40273-019-00806-4
Despite similar and reasonable fits to the observed Kaplan–Meier curve from the evaluated immuno-oncology (IO) trial, the long-term overall survival extrapolation differed substantially across the various survival models examined.
Cure, parametric mixture and landmark models may better account for the potential mechanism of action of IO treatments, whereby a plateau in long-term survival is observed.
A consistent and scientifically grounded approach to survival extrapolations is required to demonstrate the potential value of IO treatments.